Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to ...
Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, for the treatment of adult patients with symptomatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results